Search
Sumario de resultados
TIpos de contenido
Fecha
-
NewLIVERtera: Revolutionizing Cancer Research with In Silico Models and Liver Tumor Organoids
A Biotechnological Leap in the Fight Against Liver Cancer
-
New#NewAseBioAlly | “AseBio provides us with the opportunity to be part of an ecosystem facin...
Meet Fieldfisher, our new Ally. We spoke with Gemma Colomer, Principal Associte, and Arian Gallardo, Associate.
-
Press releaseBiotechnology advances in the development of key therapies for kidney diseases
It is estimated that chronic kidney disease (CKD) affects approximately 850 million people worldwide. World Kidney Day highlights that implementing global early detection policies is crucial to reduce
-
CompanyINNOPROT
-
NewBiotechnology Advances in the development of key therapies for kidney diseases
By 2040, chronic kidney disease (CKD) is projected to become the fifth leading cause of years of life lost, emphasizing the urgent need for global strategies to combat this disease.
-
NewMichael Altorfer: "BIOSPAIN 2025 offers the opportunity to connect Swiss and Spanish biote...
Meet the Swiss Biotech Association. We spoke with Michael Altorfer, CEO, to gain insights into the Swiss biotech ecosystem as the invited country for BIOSPAIN 2025.
-
AllyARPA ABOGADOS CONSULTORES
ARPA Abogados Consultores is a law firm established in 1991 in Pamplona. Their founding partners have more than 30 years experience providing economic, tax and legal advice within the business field
-
NewWomen Represent 29.2% of Management Teams in Biotechnology Companies in Spain
At AseBio, we are celebrating the third edition of the program "A Day with a Biotech Woman," which introduces female students to the inner workings of a biotechnology company and the various career
-
Press release
Women Represent 29.2% of Management Teams in Biotechnology Companies in Spain
For the past seven years, women’s participation in the biotech sector has exceeded 50%, and since 2020, the representation percentage has remained at 53%. 60% of personnel engaged in R&D activities
-
NewBionet introduces the new version of the F1 Bioreactor — your ultimate solution for versat...
All bioprocessing requirements in one, every detail of every application meticulously addressed.
-
NewThe president of Extremadura, María Guardiola, visits Natac's factory in Hervás
The head of the Government of Extremadura has been able to check the progress of the Sustainext project, a European initiative led by Natac that will transform this production center into the most
-
NewOryzon announces publication of study on Phelan-McDermid Syndrome (PMS) patients, a form o...
La revista Frontiers in Psychiatry publica un estudio que proporciona escalas clínicas y umbrales para la selección de pacientes en futuros ensayos clínicos, basados en la agresividad, la cognición y
-
NewPublic Affairs: The Roadmap That Will Shape the Future of Biotechnology
The Balearic Biotechnology and Biomedical Cluster (BIOIB) is leading a pioneering study in Spain on the impact of public affairs on this sector’s development and its social legitimization.
-
NewCONNECTA Therapeutics announces positive results from Phase I study of neurodevelopmental ...
CONNECTA Therapeutics has achieved positive results in the Phase I clinical trial of CTH120, an investigational drug that modulates neuroplasticity to treat neurodevelopmental disorders such as
-
CompanyMedTech Barcelona
-
-
NewOryzon defines Phase III Trial endpoints for Agitation and Aggression in BPD with input f...
Expertos líderes en psiquiatría en EE.UU. se unen al Comité Asesor Clínico (CAC) de Oryzon para avanzar en el desarrollo de la Fase III de vafidemstat en Trastorno Límite de la Personalidad (TLP).
-
NewAccelerating Innovation from Discovery to Development
Pharmaron accelerates drug discovery by transforming scientific breakthroughs into therapies, using advanced technologies and a global team of 8,500+ chemists. They specialize in small molecules
-
NewORYZON reports financial results and corporate update for quarter ended December 31, 2024
Se han realizado inversiones en I+D por importe de 8,3 M€, de las cuales 7,6 M€ corresponden a desarrollo y 0,7 M€ a investigación. Tras la finalización del ensayo clínico PORTICO, la intensidad en
-
NewCENER leads the bioole-up project, which will transform waste from the oil sector into rev...
CENER reaffirms its commitment to innovation and sustainability through the BIOOLE-UP research and development project, positioning itself as a benchmark in biorefinery applied to global social
-
NewBiotechnology opens the door to gene therapies for rare diseases
Despite advances in biotechnology and research, the lack of specialists, scarcity of treatments, and inequality in access to medical services remain crucial challenges for patients and their families.
